Research / TDY / Fundamental state Inspectable configuration
State dimensions Filing 0001094285-26-000043 General Corporate
Debt relative to revenue 25th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.debt_to_revenue
121.92% · OPTIONAL · VALID
Capex intensity 55th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.capex_revenue_ratio
1.83% · OPTIONAL · VALID
Operating cash generation 65th Own-history percentile · N=20
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
18.96% · OPTIONAL · VALID
Revenue growth 65th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.revenue
9.83% · CORE · VALID
Inventory pressure 85th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
70.16% · OPTIONAL · VALID
Operating margin 100th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.operating_margin
20.04% · CORE · VALID
R&D intensity RAW Current state valid · history insufficient
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
5.43% · OPTIONAL · NOT_ENOUGH_HISTORY
SBC intensity 90th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
0.84% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 46 states Self-history eligible
Oct 3, 2021 6/6 normalized Level 3 Jan 2, 2022 6/6 normalized Level 3 Apr 3, 2022 6/6 normalized Level 3 Jul 3, 2022 6/6 normalized Level 3 Oct 2, 2022 6/6 normalized Level 3 Jan 1, 2023 6/6 normalized Level 3 Apr 2, 2023 6/6 normalized Level 3 Jul 2, 2023 6/6 normalized Level 3 Oct 1, 2023 6/6 normalized Level 3 Dec 31, 2023 6/6 normalized Level 3 Mar 31, 2024 6/6 normalized Level 3 Jun 30, 2024 6/6 normalized Level 3 Sep 29, 2024 7/7 normalized Level 3 Dec 29, 2024 6/7 normalized Level 3 Mar 30, 2025 7/8 normalized Level 3 Jun 29, 2025 7/8 normalized Level 3 Sep 28, 2025 7/8 normalized Level 3 Dec 28, 2025 6/7 normalized Level 3 Mar 29, 2026 7/8 normalized Level 3 Jun 28, 2026 7/8 normalized Level 4 Period transition
What moved in the state? Balance Sheet Leverage Decreased
Previous 158.73%
Current 121.92%
Delta -36.80% Capex Intensity Decreased
Previous 1.90%
Current 1.83%
Delta -0.07% Cash Generation Increased
Previous 15.00%
Current 18.96%
Delta 3.96% Growth Increased
Previous 7.60%
Current 9.83%
Delta 2.23% Inventory Pressure Decreased
Previous 71.89%
Current 70.16%
Delta -1.73% Profitability Increased
Previous 18.86%
Current 20.04%
Delta 1.18% R And D Intensity Increased
Previous 5.42%
Current 5.43%
Delta 0.00% Sbc Intensity Increased
Previous 0.36%
Current 0.84%
Delta 0.48% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Jun 29, 2025
Similarity 86%
Compared 7 dimensions
Coverage 100% Growth 5.0 · Profitability 10.0 · Sbc Intensity 10.0 · Capex Intensity 10.0 · Cash Generation 30.0 · Inventory Pressure 0.0 · Balance Sheet Leverage 10.0 Sep 30, 2018
Similarity 73%
Compared 6 dimensions
Coverage 86% Growth 0.7 · Profitability 16.7 · Sbc Intensity 25.7 · Capex Intensity 17.2 · Cash Generation 18.3 · Inventory Pressure 51.7 Dec 28, 2025
Similarity 73%
Compared 6 dimensions
Coverage 86% Growth 0.0 · Profitability 5.0 · Capex Intensity 15.0 · Cash Generation 0.0 · Inventory Pressure 60.0 · Balance Sheet Leverage 20.0 Oct 1, 2017
Similarity 72%
Compared 6 dimensions
Coverage 86% Growth 25.0 · Profitability 14.3 · Sbc Intensity 62.7 · Capex Intensity 2.1 · Cash Generation 2.5 · Inventory Pressure 7.9 Jul 2, 2023
Similarity 71%
Compared 6 dimensions
Coverage 86% Growth 35.0 · Profitability 5.0 · Capex Intensity 25.0 · Cash Generation 40.0 · Inventory Pressure 5.0 · Balance Sheet Leverage 40.0 Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.